Fulgent Genetics Inc. (FLGT)
NASDAQ · Healthcare
Fulgent Genetics Inc. EBITDA 2014–2025
Fulgent Genetics Inc. annual/quarterly ebitda history and growth rate from 2014 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Fulgent Genetics Inc. ebitda for the quarter ending March 31, 2026 was -28.6 M, a 106.27% increase year-over-year.
- Fulgent Genetics Inc. ebitda for the twelve months ending March 31, 2026 was -66.4 M, a 66.30% increase year-over-year.
- Fulgent Genetics Inc. annual ebitda for 2025 was -67.0 M, a 36.71% increase from 2024.
- Fulgent Genetics Inc. annual ebitda for 2024 was -49.0 M, a 71.08% decrease from 2023.
- Fulgent Genetics Inc. annual ebitda for 2023 was -169.4 M, a 180.21% decrease from 2022.
- Fulgent Genetics Inc. annual ebitda for 2022 was 211.2 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Fulgent Genetics Inc. EBITDA — FAQ
Fulgent Genetics Inc. (FLGT) ebitda over the last 12 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see FLGT's ebitda history?
The chart and table above show Fulgent Genetics Inc.'s ebitda by year and by quarter, including the growth rate.